Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Selank

Selanc, TP-7

Quick Stats
Studies 114
Trials 11
Score 2
2012 pubmed 15 citations

Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia--the Find-AF study.

Wachter. Rolf R; Lahno. Rosine R; Haase. Beatrice B; Weber-Krüger. Mark M; Seegers. Joachim J; Edelmann. Frank F; Wohlfahrt. Janin J; Gelbrich. Götz G; Görlitz. Anke A; Kermer. Pawel P; Vollmann. Dirk D; Hasenfuß. Gerd G; Gröschel. Klaus K; Stahrenberg. Raoul R

Key Findings

  • Patients with NT‑proBNP above the median had about twice the rate of paroxysmal AF (17.9% vs 7.4%).
  • BNP measured at admission was the only peptide that independently predicted hidden AF in multivariate analysis.
  • BNP, NT‑proBNP and NT‑proANP had moderate accuracy (AUC 0.747, 0.638, 0.663) for detecting paroxysmal AF.

Practical Outcomes

  • If you or someone you support has had a recent stroke, checking BNP levels could help decide whether to invest in extended heart‑monitoring (like a 7‑day Holter). While not a therapy, using BNP as a screening tool may catch silent AF early, potentially reducing future cardiovascular risk.

Summary

The study shows that higher levels of the heart‑related peptide BNP (and to a lesser extent NT‑proBNP) on hospital admission can flag patients with a hidden, intermittent form of atrial fibrillation after a stroke, helping doctors decide who should get longer heart‑monitoring. This isn’t a new treatment, but it gives a simple blood test clue for spotting a risky heart rhythm that could affect overall health and longevity.

Abstract

Diagnosis of paroxysmal atrial fibrillation (AF) can be challenging, but it is highly relevant in patients presenting with sinus rhythm and acute cerebral ischemia. We aimed to evaluate prospectively whether natriuretic peptide levels and kinetics identify patients with paroxysmal AF. Patients with acute cerebral ischemia were included into the prospective observational Find-AF study. N-terminal pro brain-type natriuretic peptide (NT-proBNP), brain-type natriuretic peptide (BNP) and N-terminal pro atrial-type natriuretic peptide (NT-proANP) plasma levels were measured on admission, after 6 and 24 hours. Patients free from AF at presentation received 7 day Holter monitoring. We prospectively hypothesized that patients presenting in sinus rhythm with NT-proBNP>median were more likely to have paroxysmal AF than patients with NT-proBNP<median. 281 patients were included, of whom 237 (84.3%) presented in sinus rhythm. 220 patients naïve to AF with an evaluable prolonged Holter ECG were analysed. In patients with NT-proBNP>median (239 pg/ml), 17.9% had paroxysmal AF in contrast to 7.4% with NT-proBNP<239 pg/ml (p = 0.025). The ratio of early (0 h) to late (24 h) plasma levels of NT-proBNP showed no difference between both groups. For the detection of paroxysmal atrial fibrillation, BNP, NT-proBNP and NT-proANP at admission had an area under the curve in ROC analysis of 0.747 (0.663-0.831), 0.638 (0.531-0.744) and 0.663 (0.566-0.761), respectively. In multivariate analysis, BNP was the only biomarker to be independently predictive for paroxysmal atrial fibrillation. BNP is independently predictive of paroxysmal AF detected by prolonged ECG monitoring in patients with cerebral ischemia and may be used to effectively select patients for prolonged Holter monitoring.

Study Information

Provider

pubmed

Year

2012

Date

2012-04-11T00:00:00.000Z

DOI

10.1371/journal.pone.0034351

Citations

15

References

27